Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

08 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the third quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $3.0 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its most recent guidance for 2008 cash burn of $40 million to $50 million. The Company also reiterated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3, and are primarily due to pre-tax stock compensation expense

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

<
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... , June 25 Ruedi Waeger , Ph.D., former president ... of Directors, was honored with the Robert W. Reilly Leadership award June ... , , , ... Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities ...
... Beardsworth Consulting Group, Inc. announces the appointments of ... Robert W. Malone , M.D. as the company,s Medical Director, Vaccines. ... Dr. Alison Martin ... of clinical research experience.  She joins Beardsworth from the National Cancer Institute ...
... HOPKINTON, Mass. , June 25 Caliper Life ... and services for drug discovery and life sciences research, hosted its ... 9 and 10. This thought-leadership conference is focused on sharing ... process, leading to the next generation of breakthrough diagnostics and therapies. ...
Cached Biology Technology:Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association 2Alison Martin, MD and Robert W. Malone, MD Join Beardsworth 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 3
(Date:7/24/2014)... a low vision specialist at The University of Texas ... been awarded a grant to help Harris County residents ... or surgery. , Even with corrective lenses, many people ... there are a variety of low vision devices, such ... their vision loss. , Iyer is using the three-year, ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... the United States, wildland managers often utilize the silvicultural ... (ladder fuels). These cuttings and other post-logging debris ... in order to dispose of the material. To improve ... cover all or part of the debris pile with ... in order to keep water out. A recent study ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... of Energy,s Advanced Research Projects Agency (ARPA-E) has awarded ... Carolina State University to support research into the creation ... in high-temperature environments. "Most biofuels, such as ethanol ... plants through photosynthesis. Our project would cut out the ...
... A system that allows precise targeting of radiotherapy using ... dose of radiation they administered to lung and liver cancers ... the 2nd European Lung Cancer Conference. "With this study ... have a precise system that can give information at any ...
... is available in Spanish . , Agricultural ... Research Center in Burns, Ore., are taking a careful ... high desert rangelands. Cattle share this habitat with ... the showy commotion they create during mating season. But ...
Cached Biology News:NC State wins ARPA-E grant to study extremophile production of biofuels 2ARS scientists study effects of grazing on grouse habitat 2
... the principal excitatory neurotransmitter receptors ... glutamate receptors exist: Ionotropic receptors, ... receptors are oligomeric complexes of ... which comprise ligand-gated calcium channels. ...
Recommended fro Western blotting application...
... KLF15 is a Cys2-His2 zinc finger gene. ... liver, kidneys, heart, and skeletal muscle. ... produced in rabbits immunized with a synthetic ... KLF15 with an internal ID of P03590 ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
Biology Products: